AN2 Therapeutics, Inc.
ANTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.55
KIRA · Stoqly’s AI analyst, in plain words
- AN2 Therapeutics, Inc. lost $35.2M in fiscal 2025.
Market cap
$159M
P/E
—
Revenue
—
Net income
−$35.2M
Free cash flow
—
Operating margin
—
AN2 Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$35.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AN2 Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- AN2 Therapeutics, Inc.
- CIK
- 0001880438
AN2 Therapeutics, Inc. · ANTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$21.5M | −$41.0M | −$64.7M | −$51.3M | −$35.2M |
| Diluted EPS | −$10.64 | −$2.79 | −$2.74 | −$1.72 | −$1.16 |
| Cash | |||||
| Cash from operations | −$20.5M | −$33.5M | −$53.3M | −$49.3M | −$29.8M |
| Share count change | — | 481.5% | 53.8% | 26.4% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $58.6M | $96.1M | $107M | $83.6M | $58.0M |
| Shareholders' equity | −$47.4M | $95.4M | $125M | $81.8M | $53.1M |
| Current ratio | 17.7x | 13.7x | 7.9x | 8.4x | 6.9x |
| Returns and quality | |||||
| Return on equity | — | −170.8% | −58.8% | −49.7% | −52.1% |
| Return on tangible equity | — | −44.9% | −51.9% | −62.7% | −66.3% |
| Altman Z'' | −13.5 | 14.2 | 6.9 | 2.4 | −5.1 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.4M
6 insiders
Of sales under plans
80%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AN2 Therapeutics, Inc. · ANTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.55 a share, the company is worth $159M.
Source: SEC EDGAR XBRL filings (CIK 0001880438). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.